William Blair Starts LogicBio Therapeutics (LOGC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Chardan Capital Markets Starts LogicBio Therapeutics (LOGC) at Buy
November 13, 2018 6:47 AM ESTChardan Capital Markets analyst Gbola Amusa initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Buy rating and a price target of $20.00.
The analyst comments "LogicBios pipeline reflects a focus on indications that play to its strengths. The advantage lies in indications where 1)... More
Barclays Starts LogicBio Therapeutics (LOGC) at Overweight
November 13, 2018 4:16 AM ESTBarclays analyst Gena Wang initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Overweight rating and a price target of $24.00.
For an analyst ratings summary and ratings history on LogicBio Therapeutics click here. For more ratings news on LogicBio Therapeutics click here.
Shares of LogicBio Therapeutics closed at $13.72 yesterday.
... More